We use essential cookies and similar tools that are necessary to provide our site and services. We use performance cookies to collect anonymous statistics, so we can understand how customers use our site and make improvements. Essential cookies cannot be deactivated, but you can choose “Customize” or “Decline” to decline performance cookies.
If you agree, AWS and approved third parties will also use cookies to provide useful site features, remember your preferences, and display relevant content, including relevant advertising. To accept or decline all non-essential cookies, choose “Accept” or “Decline.” To make more detailed choices, choose “Customize.”
Customize cookie preferences
We use cookies and similar tools (collectively, "cookies") for the following purposes.
Essential
Essential cookies are necessary to provide our site and services and cannot be deactivated. They are usually set in response to your actions on the site, such as setting your privacy preferences, signing in, or filling in forms.
Performance
Performance cookies provide anonymous statistics about how customers navigate our site so we can improve site experience and performance. Approved third parties may perform analytics on our behalf, but they cannot use the data for their own purposes.
Allowed
Functional
Functional cookies help us provide useful site features, remember your preferences, and display relevant content. Approved third parties may set these cookies to provide certain site features. If you do not allow these cookies, then some or all of these services may not function properly.
Allowed
Advertising
Advertising cookies may be set through our site by us or our advertising partners and help us deliver relevant marketing content. If you do not allow these cookies, you will experience less relevant advertising.
Allowed
Blocking some types of cookies may impact your experience of our sites. You may review and change your choices at any time by selecting Cookie preferences in the footer of this site. We and selected third-parties use cookies or similar technologies as specified in the AWS Cookie Notice.
Your privacy choices
We display ads relevant to your interests on AWS sites and on other properties, including cross-context behavioral advertising. Cross-context behavioral advertising uses data from one site or app to advertise to you on a different company’s site or app.
To not allow AWS cross-context behavioral advertising based on cookies or similar technologies, select “Don't allow” and “Save privacy choices” below, or visit an AWS site with a legally-recognized decline signal enabled, such as the Global Privacy Control. If you delete your cookies or visit this site from a different browser or device, you will need to make your selection again. For more information about cookies and how we use them, please read our AWS Cookie Notice.
К сожалению, данный материал на выбранном языке не доступен. Мы постоянно работаем над расширением контента, предоставляемого пользователю на выбранном языке. Благодарим вас за терпение!
Thanks to AWS, One BioSciences is revolutionising single-cell sequencing and waging war on cancer
"Our single cell approach uses algorithms based on sequence bioinformatics that we apply to large volumes of cells. This requires a great deal of power and special GPU resources."
Hugo Cornu, Lead Tech Data at One Biosciences.
In the fast-moving biotech environment shaping the future of medical research, the emerging company, One BioSciences, has taken genetic sequencing to a new level. The company has developed a protocol able to analyse individual cells and the way in which they communicate with each other. It's a highly accurate process that could lead to new cancer treatments, but it also generates huge volumes of data. That's why One Biosciences has chosen to use Amazon Web Services (AWS) solutions to drive its research.
In the challenging field of biotechnology, One BioSciences stands out for its pioneering approach in single-cell sequencing, driven by innovative solutions from Amazon Web Services (AWS). This approach is based on a unique method for sequencing individual cells, which represents a significant leap forward compared to conventional methods. Rather than simply using one RNA profile per sample, the company has chosen to implement a cell-by-cell sequencing solution, generating tens of thousands of unique RNA profiles. This detailed approach offers a granular understanding of the genome, transcending the limitations of standard techniques.
The process starts with dissociating the sample cells, which are then encapsulated in individual drops of hydrogel, each containing one cell. Each cell is sequenced separately, enabling the analysis of a massive number of cells with unprecedented precision. This methodology reveals specific genetic profiles, providing essential information on genes associated with mechanisms of proliferation or resistance to treatment, and therefore on the development of the disease. According to Hedi Ben Brahim, CEO of One Biosciences, “the challenge is to turn these highly complex technologies into medicines as quickly as possible. Our growth is driven by the number of clinical projects (pathologies) we handle and the number of drugs under development. We start with samples and return to patients with new medicines. To do this, we have formed partnerships with a number of hospitals and research laboratories”.
Work at Cell Levels to Identify Propagation Mechanisms
One BioSciences's innovative approach lies in its ability to go beyond the mere averaging of data. Rather than treating cells as a homogeneous group, the company is using an individualised approach, examining each cell separately. This is key to understanding the genetic nuances within a tumour or diseased tissue, differentiating between cancerous cells, healthy cells and immune cells. In addition, the company has implemented a particularly innovative technology that allows it to work on frozen samples, where other players can only analyse “fresh” cells, enabling it to go faster and further than its main competitors.
Advanced genetic alignment algorithms, which are specifically adapted to the single cell level, are the backbone of this revolutionary methodology. These algorithms, usually limited to smaller-scale genetic analyses, are now being applied to huge volumes of cells, pushing back the limits of genomics research.
Instantly Available Cutting-edge Resources
The analysis process consists of reading small segments of RNA, which are then aligned with a reference human genome. Although complex, this operation is made possible by the unrivalled processing performance provided by AWS.
"We use very complex alignment algorithms," explains Hugo Cornu, Lead Tech & Data at One Biosciences. "Our single cell approach uses algorithms based on sequence bioinformatics that we apply to huge volumes of cells. This requires a great deal of power and special GPU resources."
EC2 instances and storage services such as S3 provide the scalability needed to process huge datasets efficiently, while still maintaining the speed and accuracy that the business requires. Teams at One Biosciences also rely on services such as MWAA and Athena, which give them access to cutting-edge data engineering tools without the maintenance workload that a small team can't handle on its own.
However, the close collaboration with AWS is not limited to infrastructure. AWS's machine learning abilities play a key role in the ongoing improvement of the AI algorithms used by One BioSciences. These algorithms enable more precise identification of genes associated with cancer and facilitate understanding of cellular interactions at a microscopic level.
Leading the Way to New Treatments in the Near Future
One BioSciences's unique cellular approach extends beyond simple genetic characterisation. By analysing cell by cell, the company can decipher the mechanisms of intercellular communication within a tumour. This groundbreaking approach makes it possible to understand how cancer cells interact with their environment and how these interactions contribute to tumour progression. This methodology's impact will open the way to innovative new treatments and targeted interventions. The final objective is to be able to identify and interrupt these communication mechanisms in order to hinder tumour growth, thus opening up new and personalised perspectives for cancer treatment.
Thanks to the flexibility and availability of AWS services, One BioSciences can customise its solutions, integrating technologies such as AWS Lambda to automate repetitive processes and help optimise the resources used for research. This partnership between the two companies clearly illustrates how technological innovation, combined with cutting-edge research methodology, can revolutionise the fight against cancer. One BioSciences's cell-by-cell approach is breaking down the boundaries of conventional genomics, opening up new and promising perspectives for understanding and treating a wide range of diseases. This inspiring collaboration illustrates how technological resources can be harnessed to solve some of the most complex challenges of modern medicine, opening the way to a future where cancer can be fought with unprecedented precision. A time frame that is no longer measured in decades but in months, as Hedi Ben Brahim points out: “We are now fully launched, and we are working in parallel on four specific diseases. We're giving ourselves three to four years to come up with a drug suitable for clinical trials.”
Leading Cloud Innovators in Europe
Learn how leading organizations in Europe across industries trust AWS to drive innovation at every level of their business.
Greenway Health uses AWS HealthLake to offer a fully managed certified FHIR electronic health record solution for providers, helping them serve patients more efficiently while creating a foundation for innovation.
NHS Midlands and Lancashire (NHS ML) supports nine Integrated Care Boards (ICBs) across England from its bases in the Midlands and North West, providing the high-quality transformational and back-office support they need. Using traditional methods for all patient contact was time consuming, ineffective, and expensive. The NHS ML Referral Management Centre chose AWS Partner Digital Space to migrate its patient contact center to Amazon Web Services (AWS) and deployed an automated multi-channel approach to patient communication and engagement. The innovative digital transformation of its patient waiting list management reduced waiting lists 9–14%, depending on specialty.
As the information and communications technology provider for the New South Wales (NSW) public health system, eHealth NSW supports the vital work of healthcare delivery to patients across the region. eHealth NSW moved its on-premises infrastructure to AWS to drive innovation, reduce costs by millions of dollars, and save more than 144,000 hours of productivity for front-line providers. With ten times the performance improvement in its patient records system, medical professionals get fast access to clinical data resulting in better care and outcomes.
With doctors overwhelmed by patient loads and administrative tasks, and millions of patients lacking access to their own health data, India's healthcare system stands at a critical juncture. Eka Care recognized an opportunity to use generative AI as an ‘intelligence’ to transform the healthcare system for doctors and patients.
Organizations of all sizes across all industries are transforming their businesses and delivering on their missions every day using AWS. Contact our experts and start your own AWS journey today.